Quantum Computing Inc (OTCMKTS:QUBT) is adding key medical expertise to its technical advisory board.
The Leesburg, Virginia-based technology firm said Dr Michael Liebman is joining its advisory board to add a “unique perspective” that will allow the company to apply its techniques to the pharmaceutical and healthcare sectors.
Liebman’s research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective.
“(Liebman) applies his diverse background to identify and address the challenges of real-world clinical practice and real-world patients and how these impact healthcare and the development of both diagnostics and therapeutics,” said Quantum’s CEO Robert Liscouski in a statement.
“He sees that the application of QCI’s unique approach and its highly qualified team in quantum computing to knowledge management and analysis in these areas can bring perspectives and results that were previously not attainable because of the complexity of the data and systems.”
Liebman’s work utilizes systems-based approaches and design thinking to represent and analyze risk-benefit analysis in pharmaceutical development and healthcare, Quantum told shareholders.
The new advisory board member is working closely with Quantum’s applications development team to “ensure its next product is closely aligned with the needs of the pharmaceutical industry as it moves into quantum computing,” Steve Reinhardt, Quantum’s vice president of product development said in a statement.
Liebman himself said that the combination of Quantum’s technical team and his own medical background will allow the company to make a “significant contribution” to the field.
“Billions of R&D dollars are being invested by pharmaceutical companies to develop drugs for specific populations with specific diseases,” Liebman said in a statement.
“Based on my research, I believe quantum computing techniques will have a significant impact on positive outcomes, resulting in better drug treatments and greater return on investment.”
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas